AlphAIAlphAI — Financial news for AI agents
hirunews.lkSEP 272 min read$MRNA

The first mRNA flu vaccine is now available for older adults

The FDA approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults 50+. It's now available at 13,000+ US locations. The vaccine showed 27% higher effectiveness in Moderna's study. It received standard approval for 50-64 and accelerated approval for 65+ with post-marketing study conditions.

Original reporting
hirunews.lk
Published Sep 27, 2026, 2:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 27, 2026, 4:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
The first mRNA flu vaccine is now available for older adults — source image
Source · hirunews.lk
Decision brief

The 30-second read

$MRNABullishMed
01

Why it matters

The approval creates a new revenue source and validates mRNA technology for seasonal flu, potentially influencing future vaccine development.

02

Market read

First mRNA flu vaccine approval could drive biotech stocks higher and expand mRNA platform adoption.

03

What to watch

Potential competition from traditional flu vaccines and regulatory scrutiny on accelerated approvals.

Relevance 8/10Novelty 8/10Timing: immediate availability

Background

Moderna's mFlusiva is the first FDA‑approved mRNA flu shot, offered at Walgreens and CVS.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

FDA approved Moderna's first mRNA flu vaccine for adults 50+, now available nationwide.

Expected impact

potential upside as investors price in future sales of the flu vaccine.

Evidence & confidence

First-of-its-kind approval expands Moderna's portfolio beyond COVID‑19, creating a new revenue stream.

Market effects

Sector

Boosts biotech/pharma sector outlook for mRNA platforms.

Regional

U.S. market may see modest uplift in biotech indices.

Global

Sets precedent for mRNA flu vaccines worldwide.

Counterpoint

What could challenge this read

Initial sales may be limited; production capacity and pricing could constrain impact.

Key entities

  • Company
    Moderna

    Developer of the mRNA flu vaccine.

  • Regulator
    FDA

    Granted approval for the vaccine.

Read at source← All news

Related articles

SEP 27
$MRKMedAI 8/10

How personalised mRNA vaccines are fighting melanoma

Merck and Moderna reported positive Phase 3 trial results for their personalized mRNA vaccine, intismeran autogene (mRNA-4157), combined with pembrolizumab, showing longer recurrence-free survival in high-risk melanoma patients. The vaccine is tailored to each patient's tumor mutations. Detailed data and regulatory review are pending. Accessibility in regions like India may be challenging due to high costs and infrastructure needs.

theweek.in3 min
SEP 27
$MRNALow

Moderna Begins Phase 1 Trial for Bundibugyo Ebola Vaccine

Moderna has started a Phase 1 trial in Canada for its mRNA-1469 vaccine candidate targeting the Bundibugyo strain of Ebola. The trial, supported by CEPI, will enroll 80 people to assess safety and immune response, not efficacy. No results are available yet. This is one of two Bundibugyo-specific vaccine candidates in human testing, with the other developed by the University of Oxford and the Serum Institute of India.

findarticles.com2 min
SEP 25
$BPMed

Wall Street analyst calls for the week of Sep 21–25, 2026

Wall Street analysts highlighted energy, AI infrastructure, and agriculture as key themes. BP (BP) and Chevron (CVX) were upgraded, while TotalEnergies (TTE) saw mixed views. Marathon Petroleum and Akamai (AKAM) were noted for AI infrastructure. Deere & Company (DE) rose on crop price expectations. Moderna (MRNA) faced polarizing views ahead of trial results.

investing.com3 min
SEP 25
$MRNAHighAI 8/10

Bernstein reiterates Moderna stock rating on mRNA platform progress

Bernstein reiterated a Market Perform rating and $45 price target for Moderna (MRNA), citing progress in its mRNA platform. The stock trades near its 52-week high at $194.82, with mixed analyst opinions on its valuation. Moderna announced a $2 billion convertible notes offering. Analysts have varying views, with UBS maintaining Neutral, Rothschild Redburn downgrading to Sell, and Argus upgrading to Buy.

uk.investing.com2 min
SEP 25
$MRNAHighAI 9/10

Moderna’s mFlusiva Becomes First Approved mRNA Flu Vaccine Available in US

Moderna's mFlusiva, the first mRNA-based flu vaccine, is now available in the U.S. for people 50 and older. According to the company, it was 27% more effective than standard vaccines in clinical trials. The FDA approved it for ages 50-64 via the standard process and for 65+ via an accelerated process. Side effects were mostly mild and temporary.

mezha.net2 min